Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Rhythm Pharmaceuticals, Inc. < Previous 1 2 Next > Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 June 03, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference June 03, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome May 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants May 09, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update May 07, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology April 29, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 April 24, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants April 16, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing April 01, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist March 25, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants March 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences March 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan February 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update February 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants February 08, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome February 07, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024 January 31, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants January 12, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640 January 04, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates January 04, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants December 15, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023 December 13, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event December 06, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants November 13, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update November 07, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) November 02, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 October 25, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023 October 17, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM Rhythm Pharmaceuticals Announces New Employment Inducement Grants October 13, 2023 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Tickers RYTM < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.